Kazakhstan pharmaceutical output rises 37% in 2025, hits 191 billion tenge

September 21, 2026 at 08:00 AM2 min

This digest was compiled by AI from multiple sources — links to the originals are below.

Kazakhstan's pharmaceutical market grew 31% in 2025 to 1.285 trillion tenge, with domestic production up 37% to 191 billion tenge. In the first half of 2026, output reached 126.6 billion tenge, a 30% increase from the same period last year. The Ministry of Health reported 209 pharmaceutical and medical product manufacturers operating in the country as of August 2026.

Key Facts

Kazakhstan's pharmaceutical market reached 1.285 trillion tenge in 2025, a 31% increase from the previous year.
Domestic pharmaceutical production grew 37% in 2025 to 191 billion tenge.
In the first half of 2026, pharmaceutical output totaled 126.6 billion tenge, up 30% from 97.6 billion tenge a year earlier.
Investment in the pharmaceutical industry rose 56% in 2025 to $142.8 million, with an additional $7.1 million attracted in the first quarter of 2026.
As of August 2026, 209 pharmaceutical and medical product manufacturers operated in Kazakhstan, including 43 drug producers, and local manufacturers had registered 2,994 medicines and medical devices.

Production Growth

Kazakhstan's pharmaceutical market expanded 31% in 2025 to 1.285 trillion tenge, according to the Ministry of Health. Domestic pharmaceutical output rose 37% to 191 billion tenge over the same period. In the first half of 2026, production reached 126.6 billion tenge, a 30% increase from 97.6 billion tenge in the first half of 2025. The Committee for Medical and Pharmaceutical Control reported that investment in the sector grew 56% in 2025 to $142.8 million. An additional $7.1 million was invested in the first quarter of 2026.

Manufacturers and Product Range

Kazakhstan had 209 pharmaceutical and medical product manufacturers as of August 2026, including 43 companies producing medicines. Local manufacturers had registered 2,994 medicines and medical devices by that date. The share of local producers reached 40.3% according to the marking and traceability system. Kazakhstani enterprises produce antibacterial, cardiovascular, analgesic, anti-inflammatory, and central nervous system drugs, the ministry said.

State Procurement and Investment Projects

State procurement through the single distributor SK-Pharmacy accounted for 32% of purchases from Kazakhstani manufacturers in 2025. By early 2026, 83 long-term contracts were in effect with 31 local producers for the supply of 2,022 medicines and medical devices. Kazakhstan is implementing projects with international pharmaceutical companies including AstraZeneca, Pfizer, and Roche. Since December 2025, agreements have been signed for eight investment projects to build pharmaceutical plants worth 391.3 billion tenge.